Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy

Riccardo Lencioni

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The clinical management of hepatocellular carcinoma (HCC) is often complicated by poor liver function. Treatment options for intermediate- and advanced-stage disease are limited. Transcatheter arterial chemoembolization (TACE) is an effective first-line therapy for intermediate-stage HCC. By interrupting blood flow to the tumor and administering concentrated chemotherapy locoregionally, TACE induces necrosis at the tumor site, but may create conditions that permit or encourage angiogenesis and recurrence of the tumor. Combination of TACE with new targeted agents may be an effective way to treat intermediate-stage HCC, particularly in higher risk patients. Because of the efficacy and safety of sorafenib-the first systemic therapy to show significant clinical benefit in advanced HCC-there is great interest in its potential use in combination with existing treatment modalities. The synergistic combination of TACE plus sorafenib represents a promising opportunity for tumor control.

Original languageEnglish (US)
Pages (from-to)216-224
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume83
Issue number2
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Therapeutics
Necrosis
Safety
Recurrence
Drug Therapy
Liver
sorafenib

Keywords

  • Hepatocellular carcinoma
  • Multikinase inhibitors
  • Sorafenib
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy. / Lencioni, Riccardo.

In: Critical Reviews in Oncology/Hematology, Vol. 83, No. 2, 08.2012, p. 216-224.

Research output: Contribution to journalArticle

@article{337915dfe6e04f09ab91bf0b096e0dbd,
title = "Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy",
abstract = "The clinical management of hepatocellular carcinoma (HCC) is often complicated by poor liver function. Treatment options for intermediate- and advanced-stage disease are limited. Transcatheter arterial chemoembolization (TACE) is an effective first-line therapy for intermediate-stage HCC. By interrupting blood flow to the tumor and administering concentrated chemotherapy locoregionally, TACE induces necrosis at the tumor site, but may create conditions that permit or encourage angiogenesis and recurrence of the tumor. Combination of TACE with new targeted agents may be an effective way to treat intermediate-stage HCC, particularly in higher risk patients. Because of the efficacy and safety of sorafenib-the first systemic therapy to show significant clinical benefit in advanced HCC-there is great interest in its potential use in combination with existing treatment modalities. The synergistic combination of TACE plus sorafenib represents a promising opportunity for tumor control.",
keywords = "Hepatocellular carcinoma, Multikinase inhibitors, Sorafenib, Transarterial chemoembolization",
author = "Riccardo Lencioni",
year = "2012",
month = "8",
doi = "10.1016/j.critrevonc.2011.10.008",
language = "English (US)",
volume = "83",
pages = "216--224",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy

AU - Lencioni, Riccardo

PY - 2012/8

Y1 - 2012/8

N2 - The clinical management of hepatocellular carcinoma (HCC) is often complicated by poor liver function. Treatment options for intermediate- and advanced-stage disease are limited. Transcatheter arterial chemoembolization (TACE) is an effective first-line therapy for intermediate-stage HCC. By interrupting blood flow to the tumor and administering concentrated chemotherapy locoregionally, TACE induces necrosis at the tumor site, but may create conditions that permit or encourage angiogenesis and recurrence of the tumor. Combination of TACE with new targeted agents may be an effective way to treat intermediate-stage HCC, particularly in higher risk patients. Because of the efficacy and safety of sorafenib-the first systemic therapy to show significant clinical benefit in advanced HCC-there is great interest in its potential use in combination with existing treatment modalities. The synergistic combination of TACE plus sorafenib represents a promising opportunity for tumor control.

AB - The clinical management of hepatocellular carcinoma (HCC) is often complicated by poor liver function. Treatment options for intermediate- and advanced-stage disease are limited. Transcatheter arterial chemoembolization (TACE) is an effective first-line therapy for intermediate-stage HCC. By interrupting blood flow to the tumor and administering concentrated chemotherapy locoregionally, TACE induces necrosis at the tumor site, but may create conditions that permit or encourage angiogenesis and recurrence of the tumor. Combination of TACE with new targeted agents may be an effective way to treat intermediate-stage HCC, particularly in higher risk patients. Because of the efficacy and safety of sorafenib-the first systemic therapy to show significant clinical benefit in advanced HCC-there is great interest in its potential use in combination with existing treatment modalities. The synergistic combination of TACE plus sorafenib represents a promising opportunity for tumor control.

KW - Hepatocellular carcinoma

KW - Multikinase inhibitors

KW - Sorafenib

KW - Transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=84864052036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864052036&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2011.10.008

DO - 10.1016/j.critrevonc.2011.10.008

M3 - Article

C2 - 22142656

AN - SCOPUS:84864052036

VL - 83

SP - 216

EP - 224

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -